You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Resources

  • Expand to See More

     CROI 2025 Key Data Summary

    CROI 2025 Key Data Summary

    Summary deck looking at the OPERA 3 year availability data, OPERA women subgroup data and CARES 96 week data.
    PM-IE-CBR-PPT-250001

    DOWNLOAD NOW

     Viral Blips and Low-level Viremia Pooled Analysis

    Viral Blips and Low-level Viremia Pooled Analysis

    A digital leave behind to help address concerns around viral blips for patients on Vocabria + Rekambys
    PM-IE-CBR-LBND-250001

    DOWNLOAD NOW

    aids abstract booklet

    2024 AIDS Abstract Booklet

    A digital booklet containing three abstracts from AIDS 2024, focusing on the CARLOS, BEYOND and COMBINE-2 Studies.
    PM-IE-CBR-BKLT-240001

    DOWNLOAD NOW

Patient Resources

  • Expand to See More

    V&R Patient Information Leaflet

    Vocabria + Rekambys Patient Information Booklet

    A printed booklet to provide practical information for patients post-prescription of Vocabria + Rekambys. This is to support patients to understand the treatment and ensure people living with HIV are aware of their role in treatment success.
    NP-IE-CBR-LBND-230001

    ORDER NOW

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.

These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor. 
©2024 GSK group of companies. All rights reserved.

Date of preparation: May 2025 | PM-IE-CBR-WCNT-240008